PT-141 (Bremelanotide): Completed Human Trials and What They Measured

Trial background

PT-141, also known as bremelanotide, is a melanocortin receptor agonist. Randomised placebo-controlled trials examined arousal endpoints in defined populations and reported statistically significant effects against predefined measures.

Our index references around 97 studies. The human data is what separates it from most of the library.

Reported adverse effects

Trial reporting consistently notes nausea, flushing, and transient blood-pressure changes. A vendor page that omits any mention of adverse findings is presenting an incomplete picture of the very trials it cites.

Pricing

10mg vials range from about £17 to £28 across tracked vendors, a comparatively tight band.

Supplier checks

Straightforward synthesis means purity results are usually strong. Focus on batch matching, lab identification, and whether the vendor distinguishes the research material from the licensed product.